FDA fills out genome editing product guidance with new safety recommendations
The FDA has issued new draft guidance expanding its recommendations for the development of genome editing therapies, with a focus on how sponsors should assess safety risks using next-generation sequencing. The guidance builds on the agency’s broader framework for genome editing products and reflects growing regulatory attention to off-target edits and unintended genomic changes.
The document provides more detailed expectations for nonclinical study design, data reporting and risk assessment, while highlighting the complexity of evaluating rapidly evolving technologies.
This AgencyIQ analysis explores how the guidance fits into FDA’s broader approach to genome editing and what it means for developers advancing these therapies.
Fill out the form to read the full analysis.
Required *